INTRODUCTION
============

Myotonic dystrophy (DM) is the most common form of muscular dystrophy observed in adults, and symptoms include delayed relaxation of skeletal muscles following voluntary contraction (myotonia), muscle wasting, cataracts, cardiac arrhythmia, insulin resistance, and cognitive impairment \[[@R1]\]. 98% of DM cases result from autosomal dominant inheritance of a CTG trinucleotide repeat expansion in the 3´UTR of the *Dystrophia Myotonica-Protein Kinase (DMPK)*gene \[[@R2], [@R3]\] and are classified as DM type 1 (DM1). There is a correlation between the number of *DMPK* 3´UTR CTG repeats, age of onset and disease severity, with mildly affected patients having as few as 50 repeats and more acute cases ≥1000 repeats \[[@R3]-[@R5]\]. Several mouse models expressing expanded CUG repeats (CUG~exp~) in the 3´UTR of unrelated mRNAs develop myotonia and myopathy \[[@R6]\], and DMPK knockout mice show only a subset of symptoms of DM1 \[[@R7]\]. Together this indicates that it is not loss of DMPK function that causes the phenotypes of DM1, but instead an RNA gain of function.

*DMPK CUG~exp~* transcripts form hairpin structures that are retained in nuclear foci in DM1 cells \[[@R8]-[@R10]\]. The majority of symptoms associated with DM1 are thought to result from the aberrant splicing of downstream target genes \[[@R1]\]. Best studied are the dysregulation of the splicing factors MBNL1 and CUGBP1, which either alone or in concert are sufficient to cause many of the splicing defects associated with DM1 \[[@R11], [@R12]\]. MBNL1 is normally involved in promoting muscle differentiation *via*regulation of postnatal changes in skeletal muscle splicing patterns \[[@R11], [@R13]\]. In DM1, MBNL1 binds to and is sequestered into nuclear foci by the mutant *DMPK*transcripts \[[@R14], [@R15]\]. The effect of MBNL1 loss of function is reflected in *Mbnl1* knockout mice that exhibit *Skeletal muscle-specific chloride channel 1 (Clcn1)*, *Cardiac troponin T (Tnnt2)* and *Skeletal troponin T (Tnnt3)* splicing abnormalities characteristic of DM1 \[[@R16]\]. The importance of MBNL1 function for maintenance of adult splicing patterns is highlighted by the fact that viral overexpression of Mbnl1 in skeletal muscle of a CUG~exp~ mouse model promotes adult splicing patterns for *Clcn1*, *Tnnt3* and *Sarcoplasmic/endoplasmic reticulum Ca^2+^ ATPase 1* *(Serca1)* \[[@R17]\]. Conversely, the consequences of increased CUGBP1 stability in DM1 are demonstrated in mice transgenic for human CUGBP1 in heart and skeletal muscle that show muscle degeneration and a shift towards fetal splicing patterns of several target genes \[[@R18]\]. Taken together this data suggests that identification of regulators of aberrant splicing of MBNL1/CUGBP1 target genes may aid in development of therapies targeting the underlying cause of DM1.

Patients suffering from DM1 have traditionally been limited to symptomatic treatments including anticonvulsants and pain killers for myotonia, ventilators and pacemakers to improve respiratory and cardiac function, and physical exercise to fight muscle wasting. However, since the molecular mechanisms of DM1 etiology have been unraveled, the goal of researchers has shifted to the identification of more specific therapies, for which there is an unmet medical need. Progress is being made with antisense oligonucleotides and morpholinos targeting splice sites of the MBNL1/CUGBP1 target genes such as *CLCN1* \[[@R19]\] or the *CUG~exp~* transcript \[[@R20], [@R21]\] in mouse models of DM1, but the exact mechanisms involved are still being elucidated, and delivery issues associated with intramuscular or intravenous injection of such therapies are yet to be resolved \[[@R22]\]. Small molecule compounds offer the advantage of oral formulation, and high-throughput screening (HTS) can be automated to assay millions of chemical entities in a short amount of time, even for somewhat complex cellular systems.

The key to the development of successful drug candidates from HTS hits depends largely upon the choice of the most relevant assay system for the given target \[[@R23]\]. Biochemical assays have the advantage of testing for direct interaction of chemicals with their target, however only cell-based assays allow for interrogation of pathways when the precise molecular target is unknown \[[@R24]\]. Additional advantages of cell-based assays are the ability to monitor off-target effects, cell permeability and toxicity of compounds in the same system as was used for the primary screen. Previous assays designed to identify inhibitors of specific splice enhancers \[[@R25]\] or ligands for *CUG~exp~* RNA \[[@R26]\] have been biochemical in nature and thus required secondary cell-based assays to test such factors. Given that aberrant splicing events in DM1 are both tissue- and developmental stage-specific in nature \[[@R11], [@R27]\], and that skeletal muscle is the predominantly affected tissue in DM1 patients, one of the best cell types in which to develop an assay for monitoring aberrant splicing is patient-derived myoblasts.

To that end, we have generated immortalized fibroblast and myoblast cell lines derived from healthy (*DMPK CTG~5~*) and DM1 (*DMPK CTG~1000~*) individuals, as a tool for developing HTS-compatible assays in the DM1 cellular context. We stably introduced a CLCN1 luciferase minigene construct (CLCN1-luc) into these cells as a means of monitoring *CLCN1* intron 2 retention. Aberrant inclusion of intron 2 and exon 7a in *CLCN1* transcripts is thought to be the leading cause of myotonia in DM1 patients and mouse models \[[@R28], [@R29]\], given that mutations in *CLCN1* alone are associated with dominant and recessive myotonia \[[@R30], [@R31]\], and that transgenic mouse models with *CUG~exp~* in transcripts other than *DMPK* show similar patterns of CLCN1 mis-splicing and myotonia \[[@R28]\]. We have miniaturized the CLCN1-luc assay into 1536-well format and conducted a HTS of \~13,000 small molecule compounds in triplicate, validating the DM1 patient-derived cell line and CLCN1-luc minigene reporter for use in larger screens to identify modulators of aberrant splicing and potential therapeutics for the treatment of DM1.

MATERIALS AND METHODOLOGY
=========================

Generation of Inducible MYOD Construct
--------------------------------------

The coding region of human *MYOD* was amplified from the MGC:8630 IMAGE:2961494 clone in pOTB7 backbone using PCR primers containing *Srf*I restriction sites (forward:^5\'^CGCCAGCCCGGGCCCATGGAGCTACTGTCGCCAC^3\'^ and reverse:^5\'^CGGCCAGCCCGGGCTCAGAGCACC^3\'^) and Phusion™ high fidelity DNA polymerase (NEB) as per manufacturer's instructions. Following overnight digestion with *Srf*I restriction endonuclease (NEB) this PCR product was cloned into the *Srf*I sites of a pTRE-rtTA3Zeo-SrfccdBSrf vector which was modified from the pTREautoR3 vector \[[@R32]\] (kindly provided by Dr. David Markusic) as follows. A *Zeocin* resistance gene cassette had flanking foot-and-mouth disease virus (FMDV)*2a* peptide sequences added on either side (to allow for generation of a multigene vector) and was cloned in-frame with the *tetracycline responsive transactivator ( rtTA)* gene. The 5^´^ 2a sequence was designed to end with a *Srf*I restriction site. The counter-selectable suicide gene *ccdB* was cloned into the *Srf*I site, generating pTRE-rtTA3Zeo-SrfccdBSrf. The *MYOD* PCR product was cloned into the *Srf*I sites of pTRE-rtTA3Zeo-SrfccdBSrf replacing the *ccdB* gene and generating the MYOD/pTREautoR3 vector, which has the polycistronic open reading frame *rtTA-2a-Zeo-2a-MYOD* under control of the *tetracycline responsive promoter (TRE)*. Correct orientation and reading frame were confirmed by sequencing.

Generation of CLCN1-luc Construct
---------------------------------

The genomic segment spanning exon 2 to exon 3 of human *CLCN1* (3630-4670 bp of GI:89161213) was amplified by PCR using NEB *Phusion* polymerase and 200 ng male genomic DNA as template (Promega), generating a 1 kb product with *Nco*I restriction sites at both ends (forward: ^5´^CTCTGCCATGGTTTATGGCCATCACAAAGAAC^3´^ and reverse: ^5´^GGTTAACCATGGCCTGAAGGCTTTTGGCA CTGAC^3´^). This fragment was cloned into the *Nco*I site immediately upstream of luciferase in the pGL3 promoter vector (Promega), and the ATG start codon of luciferase was mutated to TTG *via* single primer mutagenesis \[[@R33]\] using primer sequence ^5´^AGCCTTCAGGCCTTGGAAGACGCC^3´^. The CLCN1-luc construct was generated by sub-cloning the *CLCN1-luc* cassette into the pLenti6/V5-D-TOPO vector (Invitrogen) as per manufacturer's instructions. Correct orientation and reading frame were confirmed by sequencing.

Virus Production
----------------

The pBabe-puro vector expressing the catalytic subunit of human *Telomerase reverse transcriptase (hTERT)* was a kind gift from Dr. Robert Weinberg \[[@R34]\]. Retrovirus expressing hTERT was produced by co-transfection with the packaging vector pCL-10A1. 10 µg of each vector was transfected into 5 x 10^6^ 293T cells in a 10 cm tissue culture dish (Greiner) using FuGENE™ 6 (Roche) as per manufacturer's instructions. 24 h post-transfection cells were re-fed with growth media consisting of DMEM (Gibco^®^) supplemented with 10% fetal bovine serum (Hyclone) and 1X antibiotic-antimycotic (Gibco®). Viral supernatant was harvested and filtered through a 0.45 µm filter (Millipore) 48 h post-transfection.

Lentivirus expressing MYOD or CLCN1-luc was produced by co-transfection of 10 µg MyoD/pTREautoR3 or CLCN1-luc/pLenti6/V5-D-TOPO DNA with RRE, REV and VSV-g packaging vectors (6.5 µg, 2.5 µg and 3.5 µg, respectively) into 293Tcells, and viral supernatant was harvested as described above.

Generation of Immortalized Myoblast and CLCN1-luc Cell Lines
------------------------------------------------------------

Primary fibroblast cell lines GM00321 (*DMPK CTG~5~*) and GM04033 (*DMPK CTG~1000~*) were purchased from Coriell Institute for Medical Research and maintained in MEM alpha growth media (Gibco®) supplemented with 15% fetal bovine serum (FBS) (Hyclone) and 1X antibiotic-antimycotic (Gibco®). Cells were immortalized by viral infection with supernatant expressing hTERT. Briefly, 1 x 10^6^ cells were seeded in a T75 tissue culture flask (Greiner) and the next day treated with 2 ml of viral supernatant for 6 h prior to supplementation with 10 ml growth media. 48 h post-infection media was replaced and supplemented with 1 µg/ml puromycin (Hyclone). Selection was maintained for 5 days prior to cell expansion. Immortalized cell lines were subsequently infected with MYOD supernatant and selected for 14 days in growth media supplemented with 200 µg/ml zeocin (Invitrogen) and 5 µg/ml doxycycline (Sigma). The CLCN1-luc reporter gene was introduced by infection of hTERT positive, inducible MYOD positive cells with CLCN1-luc supernatant and selection for 5 days with 1 µg/ml blasticidin (Invitrogen).

Following recovery from selection, immortalized wildtype and DM1 fibroblasts were differentiated into myoblasts upon treatment with 5 µg/ml doxycycline (Sigma) for at least 24 h, or into myotubes after 3-7 days growth in differentiation media (DMEM supplemented with 2% horse serum (Hyclone) and 1X antibiotic-antimycotic (Gibco®)) containing 5 µg/ml doxycycline. All cells were maintained in 37^o^C incubators with 5% CO~2~.

RT-PCR Analysis
---------------

Total RNA was extracted from \~200,000 cultured cells grown in Greiner 6-well tissue culture treated plates using Qiagen RNeasy mini kit columns and quantified using a NanoDrop 1000 spectrophotometer (Thermo Scientific). 200 ng RNA was used as template for cDNA synthesis with random primers and SuperScript® II reverse transcriptase (Invitrogen), as per manufacturer's instructions. 1 µl of the resulting cDNA was used as template for each RT-PCR with Platinum® *Taq* DNA polymerase (Invitrogen). The following primers were used: *hTERT-pBabe3´UTR* forward - ^5\'^GAGGTGCAGAGCGACTACTC^3\'^and reverse - ^5\'^CACCC TAACTGACACACATTCC^3\'^; *TNNT2*forward - ^5\'^ATAGAA GAGGTGGTGGAAGAGTAC^3\'^ and reverse - ^5\'^GTCTCAGC CTCTGCTTCAGCATCC^3\'^; *INSR* forward - ^5\'^CCAAAGA CAGACTCTCAGAT^3\'^ and reverse - ^5\'^AACATCGCCAAG GGACCTGC^3\'^; *SERCA1* forward - ^5\'^GATGATCTTC AAGCTCCGGGC^3\'^ and reverse - ^5\'^CAGCTCTGCCTGA AGATGTG^3\'^; *CLCN1-luc* forward - ^5´^CTCTGCCATGGTTT ATGGCCATCACAAAGAAC^3´^ and reverse - ^5´^AGGGCGT ATCTCTTCATAGCCTTA^3´^; *GAPDH* forward - ^5\'^TGCACC ACCAACTGCTTA^3\'^ and reverse - ^5\'^GGATGCAGGG ATGATGTTC^3\'^. RT-PCR was performed for 35 cycles using standard PCR conditions, annealing temperature of 55^o^C and extension time of 30-60 seconds. PCR products were visualized by the addition of SYBR® Gold (Invitrogen) to samples prior to electrophoresis at 100 V using 2-3% agarose (Sigma) dissolved in Tris-acetate-EDTA buffer (Sigma) and density of bands quantified using Alpha Innotech's AlphaEase© FC software, version 3.2.1 (values expressed as average ± SEM).

Western Blotting
----------------

Total and cytoplasmic/nuclear cell extracts were prepared by lysing cells directly in 15 cm tissue culture dishes (Greiner) as per manufacturer's instructions (Active Motif). Samples were quantified by addition of Coomassie Protein Assay Reagent (Pierce) and readout with a Molecular Devices SpectraMax Plus^384^ plate reader at 595 nm. Protein samples (20-40 µg per lane) were subjected to SDS-PAGE using NuPAGE® Novex Bis-Tris 4-12% gradient precast gels (Invitrogen), and subsequently transferred onto 0.45 µm nitrocellulose membrane (Invitrogen), as per manufacturer's instructions. After incubation at room temperature with Blocker Casein in TBS (Pierce) for 1-2 h, membranes were incubated with antibody at 4^o^C overnight (with shaking). Antibodies used were specific to MYOD (1:500 sc-760 -- Santa Cruz), CLCN1 (1:1000 CLC11-A -- Alpha Diagnostic), CUG-BP1 (1:1000 05-621 -- Upstate), MBNL1 (1:100 ab49474 - abcam), LAMIN A/C (1:500 sc-20681 Santa Cruz), and β-ACTIN (1:5000 A5316 -- Sigma), and were diluted in blocking buffer supplemented with 0.1% Tween-20 (Sigma). Following washing in Tris-buffered saline with Tween-20 (TBST) (Sigma), membranes were incubated with secondary antibodies conjugated with IRDye™800 (Rockland) or Alexa Fluor®680 dye (Invitrogen) for 1 h at room temperature (1:20,000 dilution in blocking buffer supplemented with 0.1% Tween-20), washed again with TBST and visualized (and protein expression quantified) using a LI-COR Odyssey® infrared imaging system. Quantified protein levels are expressed as average ± SEM.

*In Situ* Hybridization and Immunostaining
------------------------------------------

Method adapted from Mankodi *et al*. 2001 \[[@R35]\]. Cells were grown in 39 mm cell culture dishes with 20 mm coverglass insets (*In vitro* Scientific), fixed with 4% paraformaldehyde (PFA) (Electron Microscopy Sciences) at room temperature for 20 minutes, washed in phosphate-buffered saline (PBS) (Sigma), and permeabilized by treatment with ice-cold 2% acetone (Fisher Scientific) for 5 minutes. After PBS washing cells were pre-hybridized for 1 h at 45^o^C in a wet chamber with distilled water using a buffer of 30% formamide (Sigma) and 2X saline-sodium citrate buffer (SSC) (Sigma). Hybridization was then performed in a light-proof wet chamber for 2 h at 45^o^C using the same buffer supplemented with 0.02% bovine serum albumin (BSA) (Sigma), 66 µg/ ml yeast tRNA (Sigma), 2 mM sodium (meta)vanadate (Sigma) and 1 ng/µl RNase-free HPLC-purified (CAG)~7~2\' *O*-methyl RNA probe with a phosphorothioate backbone and 5\' Alexa Fluor® 594 label (Integrated DNA Technologies). Following hybridization cells were washed 3 x 10 minutes at 45^o^C in a solution of 30% formamide and 2X SSC, then 3 x 10 minutes at room temperature (with shaking) in a 1X SSC solution. MBNL1 immunostaining was then performed on these samples by blocking with a solution of 1% FBS and 1% BSA in PBS for 1 h at room temperature and incubation with 2 µg/ ml primary antibody (in PBS) at 4^o^C overnight (M3320 -- Sigma). Antibody was washed off with 5 x 5 minute PBS washes and 1:500 Alexa Fluor®488 donkey anti-mouse secondary antibody (Invitrogen) was added for 2 h at room temperature. Following 5 x 5 minute PBS washes, cells were incubated with 7 µg/ ml Hoechst 33342 (Invitrogen) in PBS for at least 1 h at room temperature prior to imaging with a 60x/1.20W Olympus UPlanSApo objective on a Perkin Elmer Ultra*VIEW* VoX Confocal imaging system.

Immunostaining for Desmin (1:50 18-0016 - Invitrogen) and Myosin heavy chain (MHC) (1:250 18-0105 Invitrogen) was performed as for MBNL1 after fixation of cells in 24 well plates (Greiner) in 2% PFA and permeabilization with 0.25% Triton® X-100 in PBS for 5 minutes. In order to visualize cell morphology 20 µg/ml malachite green (Sigma) was added in parallel to Hoechst. Cells were imaged with a 20x/0.40 Olympus LCPlanFI objective on a Perkin Elmer Ultra*VIEW* VoX Confocal imaging system.

CLCN1-luc Reporter Gene Assay and HTS
-------------------------------------

Stable CLCN1-luc DM1 or WT cells were plated at a density of 8000 cells/well in 50 µl for 384-well format or 2000 cells/well in 6 µl for 1536-well format (in the presence of doxycycline) in tissue culture-treated Greiner custom white solid bottom plates using GNF Systems on-line screening equipment, incubated at 37^o^C with 5% CO~2~for 24 h prior to 500 nl (384-well) or 50 nl (1536-well) compound addition with a PinTool (GNF Systems) to give 1 % or 0.83% DMSO, respectively. Luciferase activity was then measured 24 h post-compound addition by the addition of 30 µl (384-well) or 3 µl (1536-well) Bright-Glo (Promega) and a 60 second luminescence read with a Viewlux^TM^ CCD Imager (Perkin Elmer). For the HTS of \~13,000 compounds in triplicate, CLCN1-luc DM1 cells were treated as described above for 1536-well format such that the final compound concentration was 8.3 µM, and the AKT V inhibitor Triciribine (Calbiochem) was included on each assay plate as a positive control.

RESULTS AND DISCUSSION
======================

Generation of Immortalized Myoblasts with Differentiation Defects Characteristic of DM1
---------------------------------------------------------------------------------------

Given the complex nature of DM1 etiology in humans, and the fact that single gene transgenic and knockout mouse models of DM1 fail to recapitulate all symptoms of the human disease \[[@R6], [@R16], [@R18], [@R36]-[@R42]\], we chose to generate immortalized DM1 patient-derived cell lines in which to develop a HTS-amenable assay. This would also allow for direct inference of assay results to the human disease condition, since signaling pathways are not always identical between mouse and human. Wildtype (WT) *DMPK CTG~5~* and DM1 patient (*DMPK CTG~1000~*) fibroblast cells were immortalized following introduction of constitutively overexpressed hTERT, which has previously been shown to allow human fibroblasts to proliferate for at least 36 population doublings \[[@R43]\]. RT-PCR confirmed expression of hTERT in immortalized WT and DM1 cell lines carrying hTERT alone (hTERT FB) or hTERT and MYOD expression constructs (MYOD FB), and was maintained upon differentiation of these cells into myoblasts and myotubes with doxycycline treatment and serum starvation (Fig. **[1A](#F1){ref-type="fig"}**). Use of fibroblasts as a starting point allowed monitoring of myogenic differentiation defects in DM1 cells upon inducible overexpression of MYOD, the sole transcription factor necessary to convert fibroblast cells into myoblasts \[[@R44]\].

As shown in Fig. (**[1B](#F1){ref-type="fig"}**), MYOD protein expression was barely detectable by Western blot 24 h after treatment of immortalized fibroblasts with doxycycline (myoblasts), but was significantly increased upon differentiation of myoblasts into myotubes for 3-7 days. Upon quantification of Western blots across multiple experiments, DM1 myotubes were observed to express between 63±4% of WT MYOD protein levels (relative to β-actin housekeeping protein). A similar trend was observed by RT-PCR (data not shown). Decreased MYOD expression has previously been reported in cells overexpressing transcripts with a *CUG~exp~* \[[@R45]\], and more recently in muscle biopsy samples of DM1 patients \[[@R46]\]. As would be expected from reduced expression of MYOD, DM1 myoblasts showed limited capacity to differentiate down the myogenic lineage, as tested by immunostaining for the early myogenic marker Desmin \[[@R47]\] and late myogenic differentiation marker MHC \[[@R48]\], together with malachite green counterstaining for morphological changes in comparison to WT cells (Fig. **[1C](#F1){ref-type="fig"}**). *In vitro* differentiation of myoblasts into myotubes is a highly variable, fluid process affected by cell density and growth conditions at the time of serum starvation, so variable morphology and stages of differentiation are often observed within one culture. Overexpression of hTERT in these cell lines may have had some effect on the differentiation potential of WT and DM1 cells, as hTERT is usually down regulated during myoblast differentiation \[[@R49]\]. However, since a significant distinction in differentiation potential (lack of Desmin expression) was reproducibly observed between WT and DM1 myoblasts prior to serum starvation, the immortalized DM1 cell lines were further characterized for their suitability to study aberrant splicing events.

Immortalized Cell Lines Show MBNL1 Localization and Splicing Defects Characteristic of DM1
------------------------------------------------------------------------------------------

Immortalized WT and DM1 cell lines were analyzed by Western blot for expression of the splicing factors CUGBP1 and MBNL1 (Fig. **[2A](#F2){ref-type="fig"}**). No significant difference in protein expression levels was observed between genotypes or throughout differentiation of the immortalized WT and DM1 fibroblasts into myoblasts and myotubes. Altered cellular distribution, increased expression levels and hyperphosphorylation of CUGBP1 protein have been reported in some DM1 patients and mouse models \[[@R50], [@R51]\], however decreased *CUGBP1* mRNA levels were reported in DM1 muscle biopsies \[[@R52]\]. In addition, MBNL1 localization to nuclear foci containing *CUG~exp~* transcripts is a more definitive trait of DM1 cells \[[@R35],[@R53]\], so cells were further analyzed for MBNL1 cellular distribution. MBNL1 protein was found to co-localize with *CUG~exp~* transcripts in nuclear foci in immortalized DM1 myoblasts (Fib. **[2B](#F2){ref-type="fig"}**), as well as DM1 fibroblasts and myotubes (data not shown). Immunostaining revealed that MBNL1 protein was evenly distributed throughout the nuclei of WT cells (data not shown), however as previously described \[[@R14]\], the acetone treatment required for *in situ* hybridization prevented visualization of this in the same experiment.

The effect of MBNL1 mis-localization upon splicing of downstream target genes in immortalized DM1 cells was tested by RT-PCR using primers specific for three of the best characterized DM1 splicing defects in *TNNT2*, *SERCA1*and *INSR* genes. These mis-splicing events are thought to contribute to the cardiac arrhythmia and insulin resistance observed in DM1 patients \[[@R1]\]. The splicing patterns observed in the WT and DM1 cell lines were as expected (Fig. **[3A](#F3){ref-type="fig"}**): exon 5 was included in 91±1% and 92±1% of *TNNT2*transcripts in DM1 myoblasts and myotubes, respectively (versus 55±2 and 53±1% in WT counterparts); exon 11 was excluded in 39±2% and 40±2% of *INSR* transcripts in DM1 fibroblasts and myoblasts, respectively (versus 14±1% and 17±1% in WT counterparts); exon 22 was excluded in 50±1% and 68±2% of *SERCA1* transcripts in DM1 myoblasts and myotubes, respectively (versus 8±1% and 21±1% in WT counterparts). Mis-splicing and expression loss of CLCN1 protein in skeletal muscle is associated with myotonia in DM1 patients and mouse models \[[@R28], [@R29]\]. Since *CLCN1* mRNA expression in cultured myoblasts is ≤ 0.01% of that in mature muscle tissue \[[@R54]\], we tested for CLCN1 protein expression levels in our immortalized WT and DM1 cell lines by Western blot (Fig. **[3B](#F3){ref-type="fig"}**). CLCN1 protein expression could only be detected in differentiated myotubes, and the expression level in DM1 myotubes was 43±1% of WT levels (determined across multiple experiments, relative to β-actin loading control). This is consistent with previous findings in DM1 patient tissue and mouse models \[[@R28]\]. Therefore the immortalized DM1 myoblast cell line was found to retain the aberrant splicing and expression loss of MBNL1/CUGBP1 target genes, and the myogenic differentiation defect associated with the disease. We proceeded to use this tool for development of a HTS-compatible assay to monitor mis-splicing in DM1.

CLCN1-luc Minigene Reporter Assay Validation
--------------------------------------------

Myotonia is one of the most prevalent symptoms of DM1 \[[@R1],[@R55]\], and aberrant inclusion of intron 2 and exon 7a of the skeletal muscle-specific chloride channel gene *CLCN1* is associated with the myotonia observed in DM1 patients and mouse models \[[@R28],[@R29]\]. Therefore we chose to generate a luciferase minigene reporter construct spanning the genomic region of exon 2 to exon 3 of human *CLCN1*, driven by the CMV promoter of the pLenti6/V5-D-TOPO vector (Invitrogen). As shown by the schematic in Fig. (**[4A](#F4){ref-type="fig"}**), the correct reading frame of the minigene was obtained upon removal of intron 2 during splicing in WT cells, however intron 2 retention in DM1 patient cells would lead to use of a premature stop codon and lack of luciferase expression. RT-PCR analysis of WT and DM1 CLCN1-luc stable cell lines with primers spanning from *CLCN1* exon 2 to the beginning of the *luciferase* coding region (Fig. **[4B](#F4){ref-type="fig"}**) demonstrated that the minigene reporter construct expressed as expected. Complete intron 2 retention was found in 43±1%, 63±1% and 72±2% of *CLCN1-luc* transcripts in DM1 fibroblasts, myoblasts and myotubes, respectively (versus 2.4±1%, 3.5±1% and 5±1% in WT counterparts), and partial intron 2 retention was seen at similar levels (14±2%) in *CLCN1-luc* transcripts of both WT and DM1 cells, in agreement with a previously identified cryptic splice site in *CLCN1* intron 2 \[[@R29]\]. Identity of all RT-PCR products was confirmed by sequencing.

Since aberrant splicing patterns of MBNL1/CUGBP1 target genes were observed in both immortalized DM1 myoblasts and myotubes, further HTS assay development was limited to myoblasts, as this allowed for easier propagation of cells, shorter incubation times prior to luciferase readout, and was not complicated by the heterogeneity of myotube differentiation stage between wells and across experiments. A panel of protein kinase B (PKB or AKT) and protein kinase C (PKC) inhibitors were screened in 384-well format for their ability to serve as a positive control by enhancing expression of the CLCN1-luc construct in DM1 myoblasts (data not shown), based on reports that CUGBP1 activation and phosphorylation is mediated by members of these kinase families \[[@R51],[@R56]\]. From these experiments only one compound, an AKT V inhibitor Triciribine (Calbiochem), enhanced luciferase expression in DM1 CLCN1-luc myoblasts by 5.3±0.4 fold 24 h after compound addition (p = 1.1 x 10^-5^ in a two-tailed t-test) (Fig. **[4D](#F4){ref-type="fig"}**), and RT-PCR analysis confirmed that this was due to partial restoration of *CLCN1-luc* splicing in treated DM1 cells (Fig. **[4C](#F4){ref-type="fig"}**). Treatment of cells with DMSO alone enhanced *CLCN1-luc* splicing in DM1 myoblasts, and was presumed to act by making RNA more accessible to general splicing factors. The splicing of *CLCN1-luc* was further improved following treatment of DM1 CLCN1-luc myoblasts with Triciribine; only 8±1% of transcripts contained intron 2 following Triciribine treatment (versus 19±2% in DMSO treated cells), and 59±2% of transcripts lacked intron 2 completely. Triciribine only gave a 1.2±0.2 fold increase in luciferase signal in CLCN1-luc WT myoblasts compared to DMSO treatment (p = 2.4 x 10^-3^), but this was not surprising given that these cells already spliced the reporter construct correctly. Given its reproducible effect on the CLCN1-luc construct in DM1 myoblasts, Triciribine was used as a positive control for miniaturization of the CLCN1-luc DM1 myoblast reporter gene assay into 1536-well format and assay validation for HTS.

Assay Miniaturization and HTS Validation of CLCN1-luc DM1 Myoblasts
-------------------------------------------------------------------

The CLCN1-luc assay in DM1 myoblasts was miniaturized from a 50 µl cell plating volume in 384-well format to a 6 µl volume in 1536-well format. The health of the CLCN1-luc DM1 myoblasts was maintained with a final DMSO concentration up to 1% in both 384-well and 1536-well formats (as determined by alamarBlue® (BioSource™), data not shown), and 0.83% DMSO (50 nl into 6 µl) was used for the HTS validation study. As shown in Fig. (**[5A](#F5){ref-type="fig"}**), miniaturization of the assay lead to a slight decrease in assay window; 5.3 fold increase in signal upon Triciribine treatment in 384-well format and 4.3 fold increase in 1536-well format. For ease of comparison with test compounds and to prevent cellular toxicity, a final concentration of 8.3 µM Triciribine was used as a positive control on all 1536-well assay plates during the HTS validation, which was the same concentration as the compounds screened.

The robustness of the CLCN1-luc assay was tested by performing a validation HTS of \~13,000 small molecule compounds in triplicate in 1536-well format. Fig. (**[5B](#F5){ref-type="fig"}**) depicts the trace of plate median relative activity for test compound wells, as well as DMSO and Triciribine control wells, and shows maintenance of an assay window of 4-fold throughout the screen, with a Z´ factor = 0.5 and CV = 9%. Thus the CLCN1-luc assay was deemed amenable to HTS. By plotting a histogram of relative activity of test compounds (Fig. **[5C](#F5){ref-type="fig"}**) a normal distribution with mean = 1.0 was observed and a hit rate of 0.26% was observed using a threshold of greater than 1.3 fold increase in CLCN1-luc signal above that of the DMSO negative control. The reproducibility of hits was 29.8%, and may be improved in future studies by raising the threshold for hit determination.

CONCLUSION
==========

We have generated an immortalized DM1 (*DMPK CTG~1000~*) fibroblast cell line that is easily induced to differentiate into myoblasts, and retains DM1 phenotypic characteristics including defective differentiation into myotubes, MBNL1 co-localization with *CUG~exp~* transcripts in nuclear foci, and mis-splicing of MBNL1/CUGBP1 target genes. In addition, we have developed the CLCN1-luc luciferase-based minigene reporter assay that monitors aberrant splicing of *CLCN1* and shows the expected increase in intron 2 retention in immortalized DM1 myoblasts in comparison to WT cells. The CLCN1-luc assay in DM1 (*DMPK CTG~1000~*) myoblasts was successfully miniaturized into 1536-well format and shown to be robust enough for HTS, and the AKT inhibitor Triciribine was identified as a useful tool compound that partially restores *CLCN1*splicing in DM1 cells. The CLCN1-luc construct was also stably introduced into WT (*DMPK CTG~5~*) and DM1 (*DMPK CTG~50~*) fibroblasts, in an identical manner to the DM1 (*DMPK CTG~1000~*) cell line, generating additional tools for triaging hits according to their dependence upon CTG repeat length. Thus we have developed an ideal system for conducting HTS to better understand and treat DM1, a complex multi-systemic genetic disease.
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![**Generation of immortalized DM1 fibroblasts, myoblasts and myotubes**. (**A**) RT-PCR confirmed *hTERT* expression in immortalized WT and DM1 fibroblasts (hTERT FB), fibroblasts containing the MYOD expression construct before (MYOD FB) and after (Myoblast) doxycycline induction, and following serum starvation-induced differentiation (Myotube), but not in primary fibroblasts (Primary FB). Equal levels of cDNA template were confirmed by amplification of the *GAPDH* housekeeping gene. (**B**) Western blot analysis confirmed inducible expression of MYOD upon differentiation of immortalized WT and DM1 cell lines into myotubes. β-actin protein expression was used to ensure equivalent amounts of total protein in each sample. (**C**) Immunostaining of immortalized WT and DM1 myoblasts and myotubes for markers of early (DESMIN) and late stage (MHC) differentiation (green), with malachite green counterstaining (red). Scale bars represent 10µm.](TOCHGENJ-4-9_F1){#F1}

![**Splicing factor expression in immortalized DM1 cells**. (**A**) Western blot analysis of CUGBP1 and MBNL1 splicing factor proteins in immortalized WT and DM1 fibroblasts, myoblasts and myotubes (with Lamin A/C and β-actin loading controls for nuclear and whole cell lysates, respectively). (**B**) Localization of DMPK mutant RNA to nuclear foci (highlighted by white arrowheads) *via in situ* hybridization with a Texas Red-conjugated RNA probe containing 7 CUG repeats ((CUG)7-TR), together with MBNL1 immunostaining (green) and Hoechst counterstaining (blue). Scale bars represent 10µm.](TOCHGENJ-4-9_F2){#F2}

![**MBNL1/CUGBP1 target gene expression in immortalized DM1 cell lines**. (**A**) RT-PCR analysis to detect splicing defects in MBNL1/CUGBP1 target genes using primers in flanking exons: *TNNT2* exon 5 (E5) inclusion, *INSR* exon 11 (E11) exclusion and *SERCA1* exon 22 (E22) exclusion in DM1 cells (in comparison to WT cells). Equal levels of cDNA template were confirmed by amplification of the *GAPDH* housekeeping gene. (**B**) Western blot analysis for CLCN1 skeletal muscle-specific chloride channel expression in immortalized WT and DM1 cell lines. β-actin protein expression was used as a loading control.](TOCHGENJ-4-9_F3){#F3}

![**CLCN1-luc minigene reporter construct splicing and expression in immortalized DM1 cell lines**. (**A**) Schematic of *CLCN1 luciferase* minigene reporter (CLCN1-luc). A genomic segment of human CLCN1 containing exon 2 to 3 and the intervening intron (solid line) was cloned downstream of the CMV promoter (CMVpr) and in-frame with the *luciferase* coding sequence in the pLenti6/V5-D-TOPO vector. Dotted lines represent correct splicing (as in WT cells). Intron 2 retention (as in DM1 cells) results in a nonsense mutation, as indicated by TGA. (**B**) RT-PCR analysis with primers spanning *CLCN1* exon 2 to the *luciferase* coding region, demonstrating complete (+ intron 2) and partial (+ partial intron 2) intron 2 retention of the CLCN1-luc construct in immortalized DM1 cells compared to WT cells (- intron 2), which was partially rescued upon treatment of CLCN1-luc DM1 myoblasts with 10 µM AKT inhibitor Triciribine (**C**). *GAPDH* was amplified as a control for equivalent cDNA synthesis. (**D**) CLCN1-luc activity (RLU = relative luciferase units) 24 h after addition of 10 µM Triciribine to CLCN1-luc WT and DM1 myoblasts (in 384-well format). \*\*\* represents a p-value = 1.1 x 10^-5^ and \* represents a p-value = 2.4 x 10^-3^ in two-tailed t-tests. Data points are an average of 3 replicates and error bars represent standard deviation.](TOCHGENJ-4-9_F4){#F4}

![**CLCN1-luc assay miniaturization and HTS validation in immortalized DM1 myoblasts**. (**A**) CLCN1-luc DM1 myoblasts were treated with 10 µM Triciribine for 24 h prior to luciferase activity readout (RLU = relative luciferase units) in 384-well and 1536-well formats. Data points are an average of 3 (384-well) or 6 (1536-well) replicates, and error bars represent standard deviation. (**B**) Activity trace of HTS of \~13,000 compounds (in triplicate) against CLCN1-luc in DM1 myoblasts in 1536-well format, showing plate median values of DMSO negative control wells (blue), Triciribine positive control wells (red), and test compounds (green), expressed as fold change relative to DMSO. An assay window of 4-fold was maintained throughout the screen (CV = 9% and Z´ factor = 0.5). (**C**) Histogram of normalized luciferase expression data (green) from HTS of \~13,000 compounds, indicating threshold of \>1.3 fold change (relative to DMSO) used to determine a hit rate of 0.26%. Red indicates 10x activity.](TOCHGENJ-4-9_F5){#F5}
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